STOCKHOLM, Sweden--(BUSINESS WIRE)--Due to the fact that the American regulatory authority, the U.S. Food and Drug Administration (FDA), has approved PERLANE for sales in the USA, Q-Med has received 29.1 MUSD from Medicis (197.4 MSEK). The payment is the last additional purchase sum from the agreement that was entered into with Medicis in 2003. The agreement has thereby generated a total purchase sum of 160 MUSD. Furthermore, Q-Med has exclusive manufacturing rights for the North American market for ten years.
